FullText URL fulltext.pdf
Author Fujihara, Miwa| Shien, Tadahiko| Shien, Kazuhiko| Suzawa, Ken| Takeda, Tatsuaki| Zhu, Yidan| Mamori, Tomoka| Otani, Yusuke| Yoshioka, Ryo| Uno, Maya| Suzuki, Yoko| Abe, Yuko| Hatono, Minami| Tsukioki, Takahiro| Takahashi, Yuko| Kochi, Mariko| Iwamoto, Takayuki| Taira, Naruto| Doihara, Hiroyoshi| Toyooka, Shinichi|
Keywords breast cancer YES1 T-DM1 dasatinib drug resistance
Published Date 2021-11-26
Publication Title International Journal Of Molecular Sciences
Volume volume22
Issue issue23
Publisher MDPI
Start Page 12809
ISSN 1422-0067
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2021 by the authors.
File Version publisher
PubMed ID 34884609
DOI 10.3390/ijms222312809
Web of Science KeyUT 000735641400001
Related Url isVersionOf https://doi.org/10.3390/ijms222312809
FullText URL fulltext.pdf
Author Iwamoto, Takayuki| Fujisawa, Tomomi| Shien, Tadahiko| Araki, Kazuhiro| Sakamaki, Kentaro| Sangai, Takafumi| Kikawa, Yuichiro| Takao, Shintaro| Nishimura, Reiki| Takahashi, Masato| Aihara, Tomohiko| Mukai, Hirofumi| aira, Naruto|
Keywords Metastatic breast cancer Endocrine therapies Estrogen receptor-positive HER2-negative Resistance
Published Date 2020-05-11
Publication Title Breast Cancer
Volume volume27
Issue issue5
Publisher Springer
Start Page 973
End Page 981
ISSN 13406868
NCID AA1103354X
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version author
PubMed ID 32394413
DOI 10.1007/s12282-020-01095-y
Web of Science KeyUT 000531780600002
Related Url isVersionOf https://doi.org/10.1007/s12282-020-01095-y
FullText URL fulltext.pdf
Author Otsuka, Yuki| Nakano, Yasuhiro| Omura, Daisuke| Iwamoto, Takayuki| Hayashi, Ruiko| Otsuka, Fumio|
Keywords autonomous functioning thyroid nodule hyperthyroidism thyroid papillary cancer toxic multinodular goiter
Published Date 2021-01-26
Publication Title Clinical Case Reports
Volume volume9
Issue issue3
Publisher Wiley
Start Page 1810
End Page 1811
ISSN 2050-0904
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2021 The Authors.
File Version publisher
DOI 10.1002/ccr3.3843
Web of Science KeyUT 000611662800001
Related Url isVersionOf https://doi.org/10.1002/ccr3.3843
FullText URL fulltext.pdf
Author Suzuki, Yoko| Taniguchi, Kohei| Hatono, Minami| Kajiwara, Yukiko| Abe, Yuko| Kawada, Kengo| Tsukioki, Takahiro| Kochi, Mariko| Nishiyama, Keiko| Iwamoto, Takayuki| Ikeda, Hirokuni| Shien, Tadahiko| Taira, Naruto| Tabata, Masahiro| Yanai, Hiroyuki| Doihara, Hiroyoshi|
Keywords Radiation-induced angiosarcoma Radiotherapy Breast-conserving surgery Breast cancer Paclitaxel therapy Adjuvant therapy of angiosarcoma
Published Date 2020-01-16
Publication Title Surgical Case Reports
Volume volume6
Issue issue1
Publisher SpringerOpen
Start Page 25
ISSN 2198-7793
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © The Author(s). 2020
File Version publisher
PubMed ID 31950295
DOI 10.1186/s40792-020-0790-7
Web of Science KeyUT 000513920900001
Related Url isVersionOf https://doi.org/10.1186/s40792-020-0790-7
JaLCDOI 10.18926/AMO/53675
FullText URL 69_5_291.pdf
Author Sugiu, Kumi| Iwamoto, Takayuki| Kelly, Catherine M.| Watanabe, Naoki| Motoki, Takayuki| Itoh, Mitsuya| Ohtani, Shoichiro| Higaki, Kenji| Imada, Takako| Yuasa, Takeshi| Omori, Masako| Sonobe, Hiroshi| Fujiwara, Toshiyoshi| Matsuoka, Junji|
Abstract Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.
Keywords breast cancer neoadjuvant chemotherapy concurrent hormone therapy estrogen receptor positive tumor response
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2015-10
Volume volume69
Issue issue5
Publisher Okayama University Medical School
Start Page 291
End Page 299
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26490026
Web of Science KeyUT 000365519600005
Author Iwamoto, Takayuki| Hara, Fumikata| Uemura, Yukari| Mukai, Hirofumi| Watanabe, Toru| Ohashi, Yasuo|
Keywords Chemotherapy-induced amenorrhea Taxane Taxane Breast cancer Guarantee-time bias Premenopause
Published Date 2020-05-28
Publication Title Breast Cancer Research and Treatment
Volume volume182
Issue issue2
Publisher Springer
Start Page 325
End Page 332
ISSN 0167-6806
NCID AA10623184
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version author
PubMed ID 32462261
DOI 10.1007/s10549-020-05692-5
Web of Science KeyUT 000539434600002
Related Url isVersionOf https://doi.org/10.1007/s10549-020-05692-5
FullText URL CCP_fulltext.pdf
Author Tsukioki, Takahiro| Shien, Tadahiko| Tanaka, Takehiro| Suzuki, Yoko| Kajihara, Yukiko| Hatono, Minami| Kawada, Kengo| Kochi, Mariko| Iwamoto, Takayuki| Ikeda, Hirokuni| Taira, Naruto| Doihara, Hiroyoshi| Toyooka, Shinichi|
Keywords Breast cancer Metformin Preoperative Tils CD8 PD-L1
Published Date 2020-06-12
Publication Title Cancer Chemotherapy and Pharmacology
Volume volume86 volume86
Issue issue1 issue1
Publisher Springer
Start Page 55 55
End Page 63 63
ISSN 0344-5704
NCID AA00598397
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders ©Author(s)
File Version Publisher
PubMed ID 32533334
DOI 10.1007/s00280-020-04092-2
Web of Science KeyUT 000539841500002
Related Url isVersionOf https://doi.org/10.1007/s00280-020-04092-2
FullText URL fulltext.pdf
Author Takahashi, Yuko| Iwamoto, Takayuki| Suzuki, Yoko| Kajiwara, Yukiko| Hatono, Minami| Tsukioki, Takahiro| Kawada, Kengo| Kochi, Mariko| Ikeda, Hirokuni| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi| Toyooka, Shinichi|
Keywords Gene expression Hormone receptor positive Residual tumor burden Targeted therapy Triple negative
Published Date 2020-04
Publication Title Clinical Breast Cancer
Volume volume20
Issue issue2
Publisher Elsevier
Start Page 117
End Page 124
ISSN 1526-8209
NCID AA11694891
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version author
PubMed ID 31570267
DOI 10.1016/j.clbc.2019.07.001
Web of Science KeyUT 000529805200021
Related Url isVersionOf https://doi.org/10.1016/j.clbc.2019.07.001
JaLCDOI 10.18926/AMO/60799
FullText URL 74_5_401.pdf
Author Tsukioki, Takahiro| Shien, Tadahiko| Ohtani, Yusuke| Fujihara, Miwa| Suzuki, Yoko| Kajihara, Yukiko| Hatono, Minami| Kawada, Kengo| Kochi, Mariko| Iwamoto, Takayuki| Ikeda, Hirokuni| Taira, Naruto| Doihara, Hiroyoshi|
Abstract Differentiated thyroid carcinoma (DTC) in juvenile patients is often an extensive and aggressive disease with a high frequency of recurrence. However, the prognosis is excellent, with a low mortality rate even when advanced disease is present, although prognostic factors and treatment strategy remain uncertain. Between April 2004 and March 2017, 33 juvenile patients (< 30 years old) were diagnosed with DTC and treated at our institution. We retrospectively investigated prognosis and factors including sex, reason for discovery, treatment, pathological factors and treatment progress to clarify the risk factors. All patients underwent curative surgical treatment. Pathologically, lymph node metastasis was identified in 25 patients (75%). Thirteen patients (39%) had bilateral cervical metastasis. In addition, 9 (27%) had more than 10 metastatic lymph nodes. The 2 patients with more than 20 metastatic lymph nodes were treated with radioactive iodine (RAI). Five patients (15%) had local recurrences and received surgery. There have been no further recurrences or deaths. However, no factors were determined to significantly predict the recurrence of juvenile DTC. Local recurrent disease was treated with surgery and/or RAI until remission, and survival was excellent in juvenile DTC.
Keywords differentiated thyroid carcinoma juvenile children
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2020-10
Volume volume74
Issue issue5
Publisher Okayama University Medical School
Start Page 401
End Page 406
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2020 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 33106695
Web of Science KeyUT 000581970100004
NAID 120006892925
JaLCDOI 10.18926/AMO/62394
FullText URL 75_4_431.pdf
Author Kunitomi, Toshiki| Nasu, Junichirou| Minami, Daisuke| Iwamoto, Takayuki| Nishie, Hiroyuki| Saito, Shinya| Fujiwara, Toshiyoshi| Matsuoka, Junji|
Abstract This study aimed to evaluate whether there are differences in the attitudes and practices of cancer pain manage-ment between medical oncologists and palliative care physicians. An online nationwide survey was used to collect responses from board-certified medical oncologists and palliative care physicians in Japan. The survey questionnaire comprised 30 questions. The differences in responses between medical oncologists and palliative care physicians were examined. Out of the 1,227 questionnaires sent, 522 (42.5%) were returned. After apply-ing the exclusion criteria, 445 questionnaires (medical oncologists: n = 283; palliative care physicians: n = 162) were retained for analysis. Among the questions about potential barriers to optimal cancer pain man-agement, both medical oncologists and palliative care physicians considered the reluctance of patients to take opioids due to fear of adverse effects as the greatest barrier. Significantly different ratings between medical oncologists and palliative care physicians were observed on 5 of the 8 questions in this area. Significantly differ-ent ratings were observed for all questions concerning pain specialists and their knowledge. For effective cancer pain management, it is important to account for differences in attitudes and practice between medical oncolo-gists and palliative care physicians.
Keywords cancer pain management opioid medical oncologist palliative care physician barriers
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2021-08
Volume volume75
Issue issue4
Publisher Okayama University Medical School
Start Page 431
End Page 437
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2021 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 34511609
Web of Science KeyUT 000697944600004
NAID 120007146037
FullText URL BreastCancer_24_4_593.pdf BreastCancer_24_4_593_tbl_fig.pdf
Author Saiga, Miho| Taira, Naruto| Kimata, Yoshihiro| Watanabe, Satoko| Mukai, Yuko| Shimozuma, Kojiro| Mizoo, Taeko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi|
Keywords BREAST-Q Breast cancer Breast reconstruction Health-related quality of life Satisfaction
Published Date 2017-03
Publication Title Breast Cancer
Volume volume24
Issue issue2
Publisher Japanese Breast Cancer Society
Start Page 288
End Page 298
ISSN 1340-6868
NCID AA1103354X
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
File Version author
PubMed ID 27179527
DOI 10.1007/s12282-016-0703-6
Web of Science KeyUT 000395524900012
Related Url isVerionOf https://doi.org/10.1007/s12282-016-0703-6
JaLCDOI 10.18926/AMO/53907
FullText URL 69_6_333.pdf
Author Ito, Maiko| Shien, Tadahiko| Kaji, Mitsumasa| Mizoo, Taeko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro|
Abstract We evaluated the usefulness of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary breast cancer. In particular, we evaluated the correlation between the maximum standardized uptake values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). Primary IDC patients operated between March 2009 and July 2013 at Okayama University Hospital were enrolled. We evaluated the correlations between the SUVmax and age, postoperative pT, histological grade, lymph vascular invasion, status of hormone receptor, human epidermal growth factor receptor 2 (HER2), Ki67 expression and node status. The Ki67 expression was classified as high (>14%) versus low (<14%). We enrolled 138 patients with IDC. Their median SUVmax was 3.85 (range:0-52.57). In a univariate analysis, the SUVmax was significantly related to age, pT, histological grade, lymphovascular invasion, hormone receptor status, HER2 status, node status and Ki67. In the 113 patients with ER-positive IDC, there was a significant correlation between Ki67 and SUVmax (p=0.0030). The preoperative 18F-FDG PET/CT results of IDC patients had significant relationships with pathological status parameters. The determination of the preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type breast cancer patients.
Keywords breast cancer invasive ductal carcinoma 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake values clinicopathological features
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2015-12
Volume volume69
Issue issue6
Publisher Okayama University Medical School
Start Page 333
End Page 338
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26690243
Web of Science KeyUT 000368434500002
FullText URL fulltext.pdf
Author Iwamoto, Takayuki| Kajiwara, Yukiko| Zhu, Yidan| Iha, Shigemichi|
Keywords Biomarker chemotherapy breast cancer gene expression
Published Date 2020-07
Publication Title Chinese Clinical Oncology
Volume volume9
Issue issue3
Publisher AME
Start Page 27
ISSN 2304-3865
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version publisher
PubMed ID 32192349
DOI 10.21037/cco.2020.01.06
Web of Science KeyUT 000543350700005
Related Url isVersionOf 10.21037/cco.2020.01.06
JaLCDOI 10.18926/AMO/54607
FullText URL 70_5_425.pdf
Author Tamura, Tomoki| Hirata, Taizo| Tabata, Masahiro| Hinotsu, Shiro| Hamada, Akinobu| Motoki, Takayuki| Iwamoto, Takayuki| Mizoo, Taeko| Nogami, Tomohiro| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi|
Abstract Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age &ge;20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer.
Keywords breast cancer phase I trial docetaxel
Amo Type Clinical Study Protocols
Publication Title Acta Medica Okayama
Published Date 2016-10
Volume volume70
Issue issue5
Publisher Okayama University Medical School
Start Page 425
End Page 427
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27777441
Web of Science KeyUT 000388098700018